Paradigm Therapeutics Secures $12.5 Million Investment to Advance Zorblisa™ Development for Epidermolysis Bullosa Paradigm Therapeutics, Inc. achieves a significant $12.5 million investment from Eshelman Ventures, LLC, aiming to complete Zorblisa™ development to treat all subtypes of Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.5 Million Investment to Advance Zorblisa™ Development for Epidermolysis Bullosa #USA #Epidermolysis_Bullosa #Paradigm_Therapeutics #Zorblisa #Mt_Pleasant

Paradigm Therapeutics Secures $12.5 Million to Advance Revolutionary EB Treatment Paradigm Therapeutics, Inc. announces a $12.5 million investment from Eshelman Ventures to support the development of SD-101, a groundbreaking therapy for Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.5 Million to Advance Revolutionary EB Treatment #USA #Epidermolysis_Bullosa #Paradigm_Therapeutics #Zorblisa #Mt_Pleasant

Paradigm Therapeutics Secures $12.5 Million Investment for Innovative EB Treatment Development Paradigm Therapeutics has announced a $12.5 million investment from Eshelman Ventures to finalize the development of Zorblisa™, a game-changing treatment for all subtypes of Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.5 Million Investment for Innovative EB Treatment Development #USA #Epidermolysis_Bullosa #Paradigm_Therapeutics #Zorblisa #Mt_Pleasant

Paradigm Therapeutics Secures $12.5 Million Investment to Advance EB Treatment SD-101 (Zorblisa™) Paradigm Therapeutics has announced a $12.5 million investment from Eshelman Ventures to support the development of SD-101, aiming to treat all types of Epidermolysis Bullosa.

Paradigm Therapeutics Secures $12.5 Million Investment to Advance EB Treatment SD-101 (Zorblisa™) #USA #Paradigm_Therapeutics #Eshelman_Ventures #Zorblisa #Mt_Pleasant